Skip to main content
Premium Trial:

Request an Annual Quote

Lion s Losses Decline FY Q1, But Bioinformatics Revenues Slide on Eve of Sale

NEW YORK, Aug. 12 (GenomeWeb News) - Lion Bioscience today reported a decline in bioinformatics revenues for the quarter ended June 30, but a significant reduction in its total losses.

 

In its earnings report for the first quarter of its 2005/2006 fiscal year, Lion separated the financial results for its bioinformatics business, which it plans to sell  by the end of the month, from its continuing operations, which it intends to maintain as a holding company following the sale of the bioinformatics business.

 

Including the bioinformatics business, which the company reported as discontinued operations, Lion posted total revenues of €1.75 million ($2.17 million) for the quarter, a 56 percent decline from €3.96 million in the year-ago period.

 

The bioinformatics group posted €1.36 million in revenues for the quarter, compared to €3.84 million in the prior-year period. Revenues for the company's continuing operations, which include royalties from its Cambridge, Mass.-based LBRI group, increased, however, to €392,000 from €125,000 in the year-ago quarter.

 

The company's total losses for the period fell to €53,000 from €2.62 million in the same period of 2004.

 

The bioinformatics group's quarterly loss was €49,000, compared to €1.7 million in the comparable period of 2004, while the loss for the company's continuing operations was €4,000, compared to €909,000 in the first quarter of 2004/2005.

 

Lion's total R&D expenses declined to €525,000 for the quarter, compared to €1.4 million in the prior-year period.

 

The company had cash and cash equivalents of €9.6 million as of June 30, and an additional €14.8 million in marketable securities.

 

"For the first time in Lion's history, we are close to a near-balanced result," said Peter Willinger, Lion's CFO, in a statement. "We are controlling our costs well and there is only a small need to use our cash reserves."

 

Willinger added that the company expects to announce the sale of its bioinformatics business "within the next few weeks."

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.